QED Therapeutics accelerates cancer drug with analytics-driven insights

CEO takeaways

• QED optimized the launch of infigratinib by leveraging custom analytics to precisely identify and characterize eligible patients for the drug
• Drawing upon patient-level, claims, prescription, genomic, diagnostic and social and behavioral data, they uncovered novel insights into genetic testing utilization and physician prescribing behaviors
• The findings refocused their commercialization efforts on lower the barriers to testing and treatment through patient and physician education


Contact Us for More Information